ASX:MSBBiotechs
Mesoblast (ASX:MSB) Is Down 7.4% After Expanding Ryoncil Access And Planning Adult SR-aGvHD Trial – Has The Bull Case Changed?
Mesoblast Limited reported past real-world use of Ryoncil (remestemcel-L-rknd) in pediatric steroid-refractory acute graft-versus-host disease, alongside expanding U.S. transplant center onboarding and broad government and commercial reimbursement coverage via a dedicated MyMesoblast access hub and a specific CMS J-Code.
The company also plans to widen Ryoncil’s label into the much larger adult SR-aGvHD population through a pivotal trial with the NIH-funded Bone Marrow Transplant Clinical...